Earnings Call Summary | Tivic Health Systems(TIVC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Tivic Health Systems(TIVC.US) Q1 2024 Earnings Conference
The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings Call Transcript:
以下是Tivic Health Systems, Inc.（TIVC）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Tivic Health reported Q1 revenue of $334,000, a decrease of 11.2% from the same quarter last year primarily due to a significant decrease in unit sales resulting from a price increase of their product, ClearUp.
Despite the drop in unit sales, the gross profit for the first quarter increased by 48% due to the ClearUP price increase and reduction in cost per unit.
The company's total operating expenses for the first quarter dropped by 26% due to lower staff consulting, decreased professional fees, and reduced general/administrative expenses.
Tivic Health公佈的第一季度收入爲33.4萬美元，比去年同期下降11.2％，這主要是由於其產品ClearUp的價格上漲導致單位銷售額大幅下降。
儘管單位銷售額下降，但由於ClearUp價格的上漲和單位成本的降低，第一季度的毛利增長了48％。
由於員工諮詢減少、專業費用減少以及一般/管理費用減少，該公司第一季度的總運營支出下降了26％。
Business Progress:
業務進展：
Tivic established a limited exclusive distribution agreement with McKesson for the distribution of ClearUP and initiated the restructuring of their supply chain to be better aligned with short-term business needs.
Tivic successfully launched a new version of ClearUP that rectified a technical issue and completed a pilot clinical study for a novel form of noninvasive vagus nerve stimulation (VNS) with Feinstein Institutes for Medical Research.
After the VNS program announcement, the company closed a $4 million financing round. The funds are expected to be used as working capital, which includes advancing the next phase of the VNS clinical program.
Tivic與McKesson簽訂了分銷ClearUp的有限獨家分銷協議，並啓動了供應鏈的重組，以更好地適應短期業務需求。
Tivic成功推出了新版本的ClearUp，該版本糾正了一個技術問題，並與費恩斯坦醫學研究所完成了對一種新型無創迷走神經刺激（VNS）的試點臨床研究。
VNS計劃宣佈後，該公司完成了400萬美元的融資。這些資金預計將用作營運資金，其中包括推進VNS臨床計劃的下一階段。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。